DrugPatentWatch Database Preview
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE Drug Profile
Which patents cover Dorzolamide Hydrochloride And Timolol Maleate, and when can generic versions of Dorzolamide Hydrochloride And Timolol Maleate launch?
Dorzolamide Hydrochloride And Timolol Maleate is a drug marketed by Akorn Inc, Anda Repository, Aurobindo Pharma Ltd, Bausch And Lomb, Fdc Ltd, Hi Tech Pharma, Lannett Co Inc, Rubicon, Sandoz, Sandoz Inc, Teva Pharms, Watson Labs Inc, and Zambon Spa. and is included in thirteen NDAs.
The generic ingredient in DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE is dorzolamide hydrochloride; timolol maleate. There are fifteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the dorzolamide hydrochloride; timolol maleate profile page.
Summary for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
| US Patents: | 0 |
| Applicants: | 13 |
| NDAs: | 13 |
| Suppliers / Packagers: | 10 |
| Clinical Trials: | 9 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE at DailyMed |
Recent Clinical Trials for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Florida | Phase 1 |
| Allergan | Phase 3 |
| Allergan | Phase 4 |
See all DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE clinical trials
Pharmacology for DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
| Drug Class | Carbonic Anhydrase Inhibitor beta-Adrenergic Blocker |
| Mechanism of Action | Carbonic Anhydrase Inhibitors Adrenergic beta-Antagonists |
